Abstract
Long-acting injectable PrEP (LAI-PrEP) is efficacious in preventing HIV among MSM and will be soon available in Europe. This study investigates the intention to use LAI-PrEP among MSM in the Netherlands by employing a diffusion of innovation approach, comparing PrEP naïve, discontinued MSM, oral PrEP early adopters and majority users. 309 MSM were surveyed on their intention and preference of LAI-PrEP. 83% showed high/very-high interest of, and 63% showed high/very-high intention to use LAI-PrEP. Early-adopters of oral PrEP use did not show increased intention to use LAI-PrEP and neither did PrEP naïve nor PrEP discontinued MSM, indicating a missing innovator effect for LAI-PrEP. Among the 218 current oral PrEP users, suboptimal oral PrEP adherence determined LAI-PrEP preference but did not determine LAI-PrEP intention. To reach the full potential of LAI-PrEP, a targeted strategy towards current oral PrEP users with suboptimal adherence seems indicated.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no funding source for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was assessed and approved by the Ethics Review Committee Psychology and Neuroscience of Maastricht University (ERCPN-174_10_12_2016).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Declarations
Funding: There was no funding source for this study.
Conflicts of interest: The authors have no relevant financial or non-financial interests to disclose.
Ethics approval: The study was assessed and approved by the Ethics Review Committee Psychology and Neuroscience of Maastricht University (ERCPN-174_10_12_2016).
Consent to participate: Informed consent was provided by all participants.
Consent for publication: Not applicable
Availability of data and material: Data are available upon request.
Code availability: Not applicable
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.